Published in Eur J Heart Fail on March 10, 2015
Global Non-interventional Heart Failure Disease Registry (REPORT-HF) | NCT02595814
Stem cell therapy for heart failure: Ensuring regenerative proficiency. Trends Cardiovasc Med (2016) 0.93
About the RICA registry in patients with heart failure. Eur J Heart Fail (2015) 0.75
REPORT-HF: the unique blend of global heart failure registry and longitudinal cohort study. Eur J Heart Fail (2015) 0.75
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol (2000) 6.08
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA (2006) 4.30
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. Arch Intern Med (2012) 3.96
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol (2014) 2.21
Heart failure: epidemiology and prevention in India. Natl Med J India (2011) 2.09
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci (2012) 1.89
International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. Eur J Heart Fail (2014) 1.58
The validity and accuracy of the Work Productivity and Activity Impairment questionnaire--irritable bowel syndrome version (WPAI:IBS). Aliment Pharmacol Ther (2004) 1.55
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53
Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. Am Heart J (2010) 1.40
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2010) 1.32
Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J (2008) 1.31
Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med (2011) 1.30
Lessons from the TOPCAT trial. N Engl J Med (2014) 1.26
Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). J Card Fail (2011) 1.23
Epidemiology of heart failure in Asia. Circ J (2013) 1.19
Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med (2014) 1.06
Design and preliminary results of the heart function assessment registry trial in Saudi Arabia (HEARTS) in patients with acute and chronic heart failure. Eur J Heart Fail (2011) 1.01
Prevalence and aetiology of heart failure in an Arab population. Eur J Heart Fail (2001) 0.98
Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. Eur Heart J Acute Cardiovasc Care (2014) 0.91
Asian Sudden Cardiac Death in Heart Failure (ASIAN-HF) registry. Eur J Heart Fail (2013) 0.91
The Caregiver Burden Questionnaire for Heart Failure (CBQ-HF): face and content validity. Health Qual Life Outcomes (2013) 0.90
Population health, outcomes research, and prevention: example of the American Heart Association 2020 goals. Circ Cardiovasc Qual Outcomes (2012) 0.85
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. Am Heart J (2014) 0.84
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Universal definition of myocardial infarction. Circulation (2007) 11.69
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med (2006) 10.63
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Third universal definition of myocardial infarction. Circulation (2012) 8.47
Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med (2013) 7.35
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
A 2-h diagnostic protocol to assess patients with chest pain symptoms in the Asia-Pacific region (ASPECT): a prospective observational validation study. Lancet (2011) 5.61
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23
Telemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis. BMJ (2007) 5.02
Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA (2007) 4.59
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J (2006) 4.57
Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction. JAMA (2012) 4.57
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J (2005) 4.37
Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol (2007) 3.92
Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol (2010) 3.63
Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol (2005) 3.53
Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 3.50
Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J (2005) 3.50
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA (2002) 3.24
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 3.18
Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail (2010) 3.01
Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol (2012) 2.98
Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med (2007) 2.95
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Is hospital admission for heart failure really necessary?: the role of the emergency department and observation unit in preventing hospitalization and rehospitalization. J Am Coll Cardiol (2013) 2.89
Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation (2009) 2.88
Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). Circulation (2010) 2.77
Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail (2007) 2.77
Airway obstruction in systolic heart failure--COPD or congestion? Int J Cardiol (2013) 2.73
Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int (2009) 2.72
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med (2010) 2.71
Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation (2011) 2.71
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. Eur Heart J (2008) 2.71
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail (2008) 2.69
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J (2014) 2.63
Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63
Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J (2007) 2.59
Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA (2011) 2.58
Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol (2011) 2.54
Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail (2010) 2.53
Clinical benefits of low serum digoxin concentrations in heart failure. J Am Coll Cardiol (2002) 2.47
Acute heart failure syndromes: current state and framework for future research. Circulation (2005) 2.47
Rapid identification and typing of listeria species by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Appl Environ Microbiol (2008) 2.46
Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med (2008) 2.42
Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol (2008) 2.39
Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J (2003) 2.37
Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol (2006) 2.37
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J Am Coll Cardiol (2008) 2.35
Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction. J Am Coll Cardiol (2009) 2.34
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J (2004) 2.32
The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J (2009) 2.28
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol (2009) 2.21